Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the initial event and statins through their vasculoprotective effect might be of value in the treatment armamentarium of PAH related to SSc.

The aim was to assess the efficacy of rosuvastatin in ameliorating vascular dysfunction and in the management of SSc-related PAH.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Faculty of Medicine, University of Alexandria; University of Alexandria
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• New York Heart Association (NYHA) class III

• A mean pulmonary artery pressure (mPAP) of > 30mmHg at rest

Exclusion Criteria:

• Smoking

• Diabetes mellitus

• Hypercholesterolemia

• Hypertension

• Cardiac insufficiency

• Coexisting hepatic and renal diseases

• Use of drugs known to interact with statins.

• Patients with severe interstitial lung fibrosis